Korea Institute of Science and Technology

K2b Therapeutics, Inc.

Shiftbio

Kist (Korea Institute of Science and Technology)

Yoo Soo Yang

In-San Kim

Sun Hwa Kim

Ick Chan Kwon

Eun Jung Lee

Jay S Kim

Hong Yeol Yoon

Jong Won Lee

HoWon J Kim

Eun-ee Koh

Kwangmeyung Kim

Gi Hoon Nam

Cherl Hyun Jeong

Gi-beom Kim

Gihoon Nam

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell

The present invention relates to a recombinant plasma membrane-based vesicle, and more specifically to a recombinant plasma membrane-based vesicle comprising a VSV-G mutated protein in which histidine, the 162amino acid, has been substituted with arginine, and a pharmaceutical composition for treating cancer comprising the recombinant plasma membrane-based vesicle.

Recombinant plasma membrane-based vesicle, for treating cancer

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.

The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention provides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface of the exosome.

Exosome-based anticancer agent

The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention provides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface thereof.

The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

Growing community of inventors

Seoul, South Korea

Yoo Soo Yang